Advertisements


Roche drug cocktail doubles chance of halting lung cancer

Adding Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts on Thursday labeled unprecedented......»»

Category: topSource: foxnewsDec 7th, 2017

Roche drug cocktail doubles chance of holding lung cancer at bay

Roche's November announcement that its Impower 150 trial had broadly succeeded in first-line lung cancer patients.....»»

Category: topSource: business-standardDec 7th, 2017

This New Drug Combination Doubles the Chance of Keeping Lung Cancer at Bay

The finding could result in annual sales of $4.6 billion by 2023. Adding Roche’s rhhvf immunotherap.....»»

Category: europeSource: fortuneDec 7th, 2017

Roche"s Lung Cancer Drug Alecensa Meets Primary Endpoint

Zacks.....»»

Category: topSource: redinewsApr 10th, 2017

Roche"s Lung Cancer Drug Alecensa Meets Primary Endpoint

Roche (RHHBY) announced that the global.....»»

Category: topSource: zacksApr 10th, 2017

Roche Announces Positive Data on Lung Cancer Drug Alecensa

Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa. Roche Holdings AG RHHBY recently announced encouraging results from the phase III study, ALUR on l.....»»

Category: topSource: zacksApr 5th, 2017

Roche Announces Positive Data on Lung Cancer Drug Alecensa

Zacks.....»»

Category: topSource: redinewsApr 5th, 2017

A drug that uses the immune system to fight cancer cells just got approved for lung cancer (RHHBY, BMY, MRK)

Thomson Reuters(Reuters) - Swiss drugmaker Roche Holding AG's new immunotherapy, Tecentriq, won approval on Tuesday from U.S. health regulators as a second-line lung cancer treatment, a decision seen likely to erode Bristol-Myers Squibb's position in this.....»»

Category: topSource: businessinsiderOct 19th, 2016

FDA Approves Genentech"s Lung Cancer Drug

Roche Group's Genentech said late Tuesday the Food and Drug Administration has approved its Tecentriq immunotherapy medicine for the treatment of certain types of lung cancer......»»

Category: topSource: foxnewsOct 18th, 2016

FDA approves Genentech"s lung cancer drug

Roche Group's Genentech said late Tuesday the Food and Drug Administration has approved its Tecentriq immunotherapy medicine for the treatment of certain types of lung cancer. Tecentriq may treat lung cancer by working with the immune system and targetin.....»»

Category: topSource: marketwatchOct 18th, 2016

Roche Alecensa Wins Second Breakthrough Status in the U.S.

Roche (RHHBY) announced that the FDA has granted a second breakthrough therapy designation for Alecensa. Roche Holding AG RHHBY announced that its lung cancer drug, Alecensa, was granted a second breakthrough therapy designation in the U.S. for.....»»

Category: topSource: zacksOct 4th, 2016

Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Roche (RHHBY) announced interim results from the phase III IMpower150 study of Tecentriq and Avastin plus chemotherapy in people with advanced form of lung cancer. Roche’s RHHBY member Genentech, annou.....»»

Category: personnelSource: nytDec 7th, 2017

Roche Reports Tecentriq/Avastin Lung Cancer Study Data

Zacks.....»»

Category: topSource: redinewsDec 7th, 2017

USFDA accepts Panacea Biotec"s ANDA for generic cancer drug

This product is a generic version of Abraxane, which is used for treatment of breast cancer, non-small lung cancer and adenocarcinoma of pancreas, it said......»»

Category: topSource: business-standardNov 30th, 2017

Roche win boosts case for adding chemo to cancer immunotherapy

Lung cancer is by far the biggest oncology market and first-line treatment provides access to the most patients.....»»

Category: topSource: business-standardNov 20th, 2017

Merck shares fall deeper into red as European lung-cancer marketing application pulled

Merck & Co. shares fell in the extended session Friday after the drug maker said it was no longer pursuing market approval for a lung cancer drug in Europe. Merck shares declined 2.3% to $56.91 after hours, adding to a 6.1% drop during Friday'.....»»

Category: topSource: marketwatchOct 27th, 2017

Biotech company aims to raise up to $22M in Austin"s next IPO; Cancer-fighting drug in advanced trials

Biotech IPOs have been pretty popular in Austin in recent years. The latest one comes from a company battling non-small cell lung cancer that intends to price its offering at $5 a share......»»

Category: topSource: bizjournalsOct 24th, 2017

Spectrum Pharma Investors Optimistic Over New Lung Cancer Drug

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) shares are trading higher by $7.20 (50 percent) at $21.66 in Wednesday's session. read more.....»»

Category: blogSource: benzingaOct 18th, 2017

Bristol-Myers Gets a Boost

The Checkmate-227 drug trial evaluating non-small cell lung cancer is raising sentiment......»»

Category: topSource: barronsOct 16th, 2017

Lilly"s (LLY) Verzenio Fails in Phase III Lung Cancer Study

Lilly's breast cancer drug, Verzenio, failed to achieve primary e.....»»

Category: personnelSource: nytOct 11th, 2017

Eli Lilly Shares Spike On Patent Victory

The U.S. Patent and Trademark Office ruled in favor of Eli Lilly and Co (NYSE: LLY) Thursday in an inter partes review of the ’209 patent for Alimta, a chemotherapy drug for lung cancer. read more.....»»

Category: blogSource: benzingaOct 5th, 2017